Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline sees EU approve first vaccine for rotavirus

GlaxoSmithKline sees EU approve first vaccine for rotavirus

28th February 2006

The first vaccine for the diarrhoea-causing rotavirus gastroenteritis has been approved within Europe.

Developed by GlaxoSmithKline (GSK), Rotarix can be administered to children between two and four months, immunising them to the virus prior to the peak ages for contracting the disease.

Rotavirus puts 87,000 European babies into hospital every year, and affects 3.6 million children under five years old across the continent. It is thought that the disease kills 600,000 children a year in the developing world.

Professor Dr Timo Vesikari of University of Tampere in Finland, said: “Rotavirus causes great discomfort for children, with diarrhoea and vomiting continuing for several days, which can lead to severe dehydration and if left untreated can be fatal.

“The availability of a safe and effective vaccine, like Rotarix, is exciting news for physicians as it will not only prevent these distressing symptoms that many children suffer, but will also help to reduce the burden on healthcare resources needed in treating outbreaks of the disease.”

Rotarix has already been approved for use within 33 countries, while over a million doses have also been given to children in Mexico.

track© Adfero Ltd

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.